Drug News

Added 8 hours ago Drug news

Dermavant Sciences acquires rights to tapinarof from GSK. This is an investigational therapeutic aryl hydrocarbon receptor modulating agent for the treatment of psoriasis and atopic dermatitis.

GSK has announced that Dermavant Sciences, a subsidiary of Roivant Sciences, has agreed to purchase the rights to tapinarof, an...

Added 8 hours ago Drug news

Baloxavir marboxil success in Phase III CAPSTONE-2 study to treat influenza.- Genentech/Roche + Shionogi.

Genentech, announced that the Phase III CAPSTONE-2 study assessing the safety and efficacy of baloxavir marboxil in people at high...

Added 1 day ago Drug news

Enzyvant initiated its rolling submission to the FDA of a BLA for RVT 802 to treat complete DiGeorge Anomaly effects.

Enzyvant, has initiated its rolling submission of a Biologics License Application (BLA) for RVT 802 to the FDA. The company...

Added 2 days ago Drug news

FDA approves expanding indication of the Elecsys BRAHMS PCT assay to aid antibiotic treatment in infection.- Roche.

Roche announced that it has received clearance from the FDA for the expanded use of its Elecsys BRAHMS PCT assay...

Added 2 days ago Drug news

FDA approves Xtandi for non-metastatic prostate cancer.- Astellas + Pfizer.

Astellas Pharma and Pfizer announced the FDA approved a supplemental New Drug Application (sNDA) for Xtandi (enzalutamide), following FDA Priority...

Added 2 days ago Drug news

FDA approves Tpoxx for smallpox.- SIGA Technologies.

The FDA has approved Tpoxx (tecovirimat), from SIGA Technologies, as the first drug with an indication for treatment of smallpox....

Added 2 days ago Drug news

FDA advisory committee recommends approval of Krintafel for malaria.- GlaxoSmithKline.

The Antimicrobial Drugs Advisory Committee (AMDAC) of the FDA voted that there is substantial evidence of the effectiveness (13 for;...

Added 3 days ago Drug news

Sight Diagnostics received a CE mark for its point-of-care blood diagnostic device, OLO.

Sight Diagnostics received a CE mark for its point-of-care blood diagnostic device, OLO, which uses artificial intelligence to optically read...

Added 3 days ago Drug news

NEJM publishes results of CELESTIAL trial of Cabometyx in patients with previously treated advanced hepatocellular carcinoma.- Ipsen + Exelixis.

Ipsen announced that The New England Journal of Medicine (NEJM) published results from the CELESTIAL phase III pivotal trial of...

Added 3 days ago Drug news

NICE does not recommend Darzalex plus chemo for second line use in multiple myeloma.- Janssen Biotech.

The UK NICE has issued draft guidance not recommending Darzalex (daratumumab), from Janssen Biotech, for second line use in multiple...

Search all news articles